vimarsana.com

Latest Breaking News On - Kala pharmaceuticals inc - Page 9 : vimarsana.com

Kala Pharmaceuticals Announces Appointment of Marjan Farid,

ARLINGTON, Mass., Nov. 01, 2022 (GLOBE NEWSWIRE) Kala Pharmaceuticals, Inc. (NASDAQ: KALA) (“Kala” or the “Company”), a clinical-stage.

University-of-california-irvine
California
United-states
San-diego
American
Marjan-farid
Los-angeles
Mark-iwicki
Hannah-deresiewicz
University-of-california
Severe-ocular-surface-disease-center
Gavin-herbert-eye-institute

Kala Pharmaceuticals (KALA) Appoints Marjan Farid to its Board

Kala Pharmaceuticals (KALA) Appoints Marjan Farid to its Board
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

University-of-california-irvine
California
United-states
San-diego
American
Marjan-farid
Los-angeles
Mark-iwicki
University-of-california
Severe-ocular-surface-disease-center
Gavin-herbert-eye-institute
Kala-pharmaceuticals-inc

Kala Pharmaceuticals Announces Reverse Stock Split

Kala Pharmaceuticals Announces Reverse Stock Split
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United-states
American
Hannah-deresiewicz
Exchange-commission
Company-board-of-directors
Alcon-inc
Drug-administration
American-stock-transfer-trust-company
Kala-pharmaceuticals-inc
Nasdaq
Stock-will-begin-trading
Split-adjusted-basis

The Worldwide Topical Drugs Industry is Expected to Reach $217 Billion by 2030

/PRNewswire/ The "Global Topical Drugs Market Size, Share & Trends Analysis Report by Type (Semi-solid, Liquid), by Route Of Administration (Dermal,.

United-states
Canada
Dublin
Ireland
America
American
Laura-wood
Medpharm-ltd
Movement-analysis
Key-company-market-share-analysis
Merck-co
Burn-centers

Alcon Inc. Swiss: Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio

Builds on Alcon's existing commercial expertise in the estimated $20 billion global ophthalmic pharmaceutical segment1 Adds Rocklatan and Rhopressa, and a pipeline of several clinical and

United-states
China
Geneva
Genè
Switzerland
Fribourg
Russia
Ukraine
Canton
Swiss
Steven-smith
Allen-trang

vimarsana © 2020. All Rights Reserved.